Aegis Sciences Corporation Announces Updates for NPS Testing

NASHVILLE, TN. (April 1, 2024) – Aegis Sciences Corporation, a health care testing lab based in Nashville, TN, is pleased to announce another expansion of novel psychoactive substance (NPS) testing for its clients. This update is a revision of the NPS test menu, to include the removal of analytes which have significantly decreased in prevalence, as well as the addition of new analytes which have entered circulation in the United States.

To stay current with the rapidly changing landscape of new and emerging drugs, Aegis recently committed to bi-annual NPS test menu updates to include the tier one and tier two recommendations established collaboratively by the Center for Forensic Science Research and Education (CFSRE) and the Society of Forensic Toxicologist (SOFT) NPS Committee. The CFSRE and the SOFT NPS Committee’s recommendations for NPS were designed to assist laboratories seeking guidance on which NPS and other emerging drugs they should test. Analytes in Aegis’s current method align with CFSRE’s Scope Recommendations for Quarter 4 of 2023.

“Our most recent update demonstrates our commitment to providing the most relevant testing available to healthcare providers,” said Dr. Rebecca Heltsley, Senior Vice President, Research and Development at Aegis Sciences Corporation.

Health care practitioners can learn more about the updated test offering through the Aegis website:

About Aegis Sciences Corporation

Founded in 1990, Aegis Sciences Corporation is a laboratory sciences company based in Nashville, Tenn., that provides science-driven testing and consulting services for clients such as health care providers, pharmaceutical companies, professional and amateur sports organizations, leading college and university athletic programs, Fortune 500 corporations, and government agencies throughout the United States. For more information, please visit


For more info please visit:


Sign up for the Aegis Newsletter